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There was a time when a simple dichotomy charac-
terized many health economic evaluations. On the
one hand there were those economic appraisals that
were conducted alongside clinical trials and which
commonly employed statistical methods in so-called
stochastic evaluations. On the other, there was the
use of decision analytic modeling to synthesize data
from secondary sources in order to estimate cost-
effectiveness in a deterministic fashion. Now, how-
ever, the distinctions are becoming ever more
blurred. The limitations of single trials as the sole
vehicle for economic appraisal is widely reported
[1] and, in particular, the continued need for mod-
eling to adapt trial-based analyses is well under-
stood [2]. Furthermore, the use of probabilistic
sensitivity analysis to represent uncertainty in mod-
eling studies offers the opportunity to make statis-
tical statements about the impact of parameter
uncertainty for cost-effectiveness estimates from
deterministic models.
The trend toward a more statistical approach to
handling uncertainty in cost-effectiveness models
has been picked up in the new guidance from the
National Institute for Clinical Excellence (NICE) in
the UK. NICE now advocates the use of a reference
case set of methods for those making submissions to
its appraisal process [3]. Included within this refer-
ence case is the recommendation to use probabilistic
sensitivity analysis to represent parameter uncer-
tainty. Journal editors and reviewers too are becom-
ing more stringent in their requirements to see the
use of probabilistic methods to characterize param-
eter uncertainty. In this issue of 
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,
Oostenbrink and colleagues [4] present a probabil-
istic model that typiﬁes the approach to presenting
uncertainty in such models. By characterizing the
uncertainty in the input parameters of their model
as probability distributions, the authors are able to
propagate that uncertainty through the model using
Monte Carlo simulation, thus generating a joint
distribution in the incremental costs and effects
that represents the consequences of the input para-
meter uncertainty. This is presented on the cost-
effectiveness plane and can be summarized using
cost-effectiveness acceptability curves just as any
statistical analysis of costs and effects from a trial-
based analysis.
Probabilistic methods are not universally
accepted, however. A common criticism levied at
the use of probabilistic analysis is that the choice of
distribution is essentially arbitrary and generates
another aspect of the analysis that must itself be
subjected to sensitivity analysis. Although it is true
that the literature contains many examples of prob-
abilistic sensitivity analyses that employ arbitrary
distributional forms, this is generally because the
authors have not thought carefully about the uncer-
tainty in the parameter they are seeking to capture.
Although there are clearly a large number of poten-
tial distributions available in the software packages
used to produce cost-effectiveness models, it does
not follow that they are all candidate distributions
for every possible parameter. For any given param-
eter in a decision model, the choice of distribution
to characterize uncertainty in that parameter should
be chosen from a small number of candidate distri-
butions which will depend on the data from which
the parameter is estimated and the method of esti-
mation. For example, a normal distribution is
always a candidate for any parameter based on
expected values because of the role of the 
 
Central
Limit Theorem,
 
 which essentially states that the
sampling distribution of the mean will be normally
distributed whatever the underlying distribution of
the data with sufﬁcient sample size. Of course, mod-
els will often be employed in situations where sam-
ple sizes of data informing parameter estimation
cannot be relied on to be sufﬁcient and other distri-
butional forms are required. Probability parame-
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ters, for example, are constrained on the interval
zero to one, and distributional forms that are con-
sistent with this restriction should be chosen. If
binomial data are available to estimate a simple
proportion, then the Beta distribution is the obvious
candidate distribution for the probability because of
its special relationship with binomial data [5]. If the
probability parameters are estimated from a logistic
regression, then the appropriate assumption is nor-
mality on the log-odds scale. Similarly, single costs
can be assigned a gamma distribution, or lognormal
distribution if estimates of costs come from a log-
scale regression model.
The point is that far from involving arbitrary
assumptions and choices, application of probabilis-
tic methods encourages the analyst to think care-
fully about the appropriate distribution and
variance to represent the uncertainty in a given
model parameter, based on the empiric data inform-
ing the estimation of that parameter. In general,
these distributions will be the exact same distribu-
tions that form the basis of standard methods for
conﬁdence interval estimation for given parameter
types that can be found in any medical statistics or
econometric textbook. Appropriately undertaken,
probabilistic analysis will give a more accurate
depiction of the importance of parameter uncer-
tainty for the results of the analysis in comparison,
say, to simple univariate sensitivity analysis.
Although choice of distributional form and esti-
mation of variance may be straightforward when
primary data are available, what should the analyst
do when primary data are not available—when
parameters are informed by secondary information
from the literature, or perhaps even by expert opin-
ion? Is this a situation where univariate sensitivity
analysis should be used? I would suggest not. Even
in these situations, probabilistic methods can and
should be used to characterize uncertainty. Inevita-
bly, in the absence of primary data, the role of sub-
jective opinion of the analysts will be greater in
determining the variance of distributions. The
choice of distributional form, however, should be
guided by the type of parameter and the sort of pri-
mary data that would in principle be available to
inform the estimation of the parameter if additional
data collection was initiated.
A ﬁnal thought on the use of probabilistic meth-
ods and the role of traditional sensitivity analysis: It
is important to recognize that the use of probabil-
istic methods is primarily advocated for repre-
senting parameter uncertainty. Other types of
uncertainty continue to be important, in particular,
uncertainty relating to the structure and assumption
of decision models [6]. In the article by Oostenbrink
and colleagues [4], a series of sensitivity analyses is
presented looking at the consequence of changing
different assumptions and scenarios. This represents
an important continuing role for traditional sensi-
tivity analysis to be used alongside probabilistic
methods.
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